In recent years, some clinical study demonstrated that combination of anti-VEGF agents and ICIs prolongs survival compared to anti-VEGF alone in multiple carcinomas such as renal cell carcinoma and hepatocellular carcinoma (17, 18). The gene discussed is VEGFA; the disease is hepatocellular carcinoma.